SynthesisUpdates in surgery2025
Neoadjuvant chemoradiotherapy with or without preoperative immunotherapy for locally advanced rectal cancer: a system review and meta-analysis.
Synthesis in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of nomogram about conversion from temporary to permanent stoma in rectal cancer based on machine learning and traditional model-does robotic surgery have competitive advantages?Journal of robotic surgery · 2026Article
- Mitochondrial fitness in circulating T cells predicts neoadjuvant therapy response in locally advanced colorectal cancer.Gastroenterology report · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
For locally advanced rectal cancer (LARC), adding immunotherapy after patients receive standard neoadjuvant chemoradiotherapy (nCRT) or short-course radiotherapy (SCRT) is a new method. This study aims to evaluate the efficacy and safety of the combination of nCRT/SCRT and immunotherapy on LARC patients based on the current published studies. A comprehensive electronic search of literature up to December 1, 2024 was carried out in Pubmed, the Cochrane Library, Web of Science, Google Scholar databases and Embase. Studies comparing the nCRT/SCRT with preoperative immunotherapy (nCRT/SCRT + IMT group) and nCRT/SCRT alone (nCRT/SCRT group) were included. The primary outcome was the pathological complete response (pCR) rate. Three randomized control trials and one retrospective study, involving 692 LARC patients, were included. The pooled pCR rate was 40.6% (134/330) in the nCRT/SCRT + IMT group and 22.5% (66/293) in the nCRT/SCRT group (RR = 1.68, 95% CI 1.11-2.55, p = 0.01). The pTRG 0-1 rate was 69.0% (180/261) in the nCRT/SCRT + IMT group and 47.1% (106/225) in the nCRT/SCRT group (RR = 1.43, 95% CI 1.22-1.68, p < 0.001). The major adverse events rate (grade 3-4) were comparable between the nCRT/SCRT + IMT group and the nCRT/SCRT group (61/194, 31.4% vs 51/197, 25.9%, RR = 1.22, 95% CI 0.90-1.65; P = 0.20). Preoperative immunotherapy in combination with standard nCRT/SCRT may improve the tumor regression and increase the pCR rate in selected LARC patients without additional major treatment adverse events.
Indexed as
Identifiers
40616745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.